Glucagon-like peptide-1 receptor agonists, usually shortened to GLP-1 receptor agonists, are a class of peptide-based compounds that bind to a specific receptor found in the gut, the pancreas, and crucially, the brain. Researchers have long studied them for their role in blood-sugar regulation and appetite signaling. A newer line of inquiry asks whether the same receptor pathways that shape eating behavior might also shape reward-related behaviors, including the desire to drink alcohol.
A systematic review published in the Journal of Clinical Medicine in 2026 set out to gather and evaluate all available clinical evidence on this question. The authors searched two major scientific databases, covering studies from their earliest records through December 2025, and ultimately included five studies representing nearly 50,000 participants. The findings are cautiously interesting, though the researchers are clear that the evidence is still early and uneven.
Why the brain connection matters
GLP-1 receptors are not only located in metabolic tissue. They appear throughout the central nervous system, including regions associated with reward processing and impulse regulation. This is the theoretical foundation for the research: if activating these receptors damps down the appeal of highly palatable food, it is plausible, at least mechanistically, that it might also reduce the motivational pull of alcohol.
Animal studies had already suggested this connection before clinical researchers began investigating it systematically in humans. The systematic review was designed to assess whether those signals translate into measurable changes in people who drink heavily or who carry a diagnosis of alcohol use disorder.
Structure of the systematic review
The authors followed PRISMA 2020 guidelines, a standard framework for conducting and reporting systematic reviews. Two independent reviewers handled data extraction and assessed each study for risk of bias using validated tools. Only studies that reported actual quantitative measures of alcohol consumption were included, meaning studies had to go beyond self-report questions and include objective metrics where possible.
The final pool included three randomized controlled trial-based analyses and one large observational cohort study. The compounds examined across these studies were semaglutide, dulaglutide, and exenatide. All three are peptides that act on the GLP-1 receptor, though they differ in their molecular structure, half-life, and potency.
Results by compound
Semaglutide and dulaglutide were associated with modest but statistically significant reductions in alcohol consumption and craving in several of the included studies. The review notes improvements in selected behavioral outcomes, meaning that across particular measurement tools and subgroups, the reductions met the threshold for statistical significance rather than being attributed to chance alone.
Exenatide told a different story. In the overall population of participants with alcohol use disorder, exenatide did not produce significant effects. The review does mention that signals appeared in certain subgroups, but those findings were limited and would need replication before drawing any firm conclusions.
The large cohort study, which is an observational design rather than a controlled experiment, found small but statistically significant reductions in AUDIT-C scores after participants began a GLP-1 receptor agonist. The AUDIT-C is a short clinical screening tool that measures alcohol consumption frequency, quantity, and binge behavior. Even small shifts on this scale can carry population-level relevance when the dataset involves tens of thousands of people.
Objective measurement and its limits
One of the more technically important aspects of the review involves how alcohol use was actually measured. Self-reported drinking is notoriously unreliable, so researchers often supplement it with biological markers. The review notes that objective measures including phosphatidylethanol, known as PEth, and breath alcohol concentration did show reductions in selected contexts.
PEth is a direct biomarker of alcohol intake that accumulates in red blood cells and provides a window into consumption over roughly the prior two to four weeks. Its inclusion in some studies adds credibility to the self-reported reductions. However, the review specifically flags that these objective measures were only reported in a small number of studies, which limits how confidently the finding can be generalized.
Heterogeneity and what it means
The authors describe the overall evidence as limited and heterogeneous. Heterogeneity is a technical term in systematic reviews that signals meaningful differences between studies in their design, populations, interventions, or outcome measures, differences large enough that the results cannot be simply averaged together.
In this case, the studies varied in which GLP-1 receptor agonist was used, what dose was administered, how long participants were followed, what population was enrolled, and how alcohol outcomes were defined and measured. That variability makes it difficult to arrive at a single clean conclusion. One study's positive finding may reflect a different underlying mechanism, a different severity of alcohol use at baseline, or a different study design compared to another study that found no effect.
This is not unusual at this stage of research. It typically signals that the field is in an early, exploratory phase where promising signals exist but rigorous confirmation has not yet followed.
What comes next in the research
The systematic review concludes with a clear call for larger and more rigorously designed randomized controlled trials. Specifically, researchers need trials that are powered to detect meaningful differences, follow participants for longer periods, use consistent and validated measures of alcohol consumption, and enroll populations that are well-characterized in terms of their drinking severity and any co-occurring conditions.
The review also implicitly raises a question the field has not yet fully answered: whether any observed effects on alcohol use are a direct pharmacological consequence of GLP-1 receptor activation in reward circuits, or whether they are an indirect result of broader changes in appetite, general impulsivity, or metabolic state. Distinguishing between those mechanisms would help researchers understand who is most likely to respond and why.
For now, the literature suggests that GLP-1 receptor agonist peptides represent an intriguing area of investigation in the context of alcohol use research. The evidence is not strong enough to draw clinical conclusions, but it is consistent enough to justify the larger trials the authors are recommending.
